Royalty Report: Drugs, Disease, Therapeutic – Collection: 240085

License Grant

For the Research, Development, Marketing and Manufacturing License, Licensor grants to the Japanese Licensee,  a non-exclusive license, or, in the case of any Third Party Patent Rights licensed to Licensor a non-exclusive sublicense, including the right to grant sublicenses, under the Patent Rights licensable or sublicensable by Licensor, including Licensors rights in any jointly owned Patent Rights, to further develop Research Compounds in connection with the development of pharmaceutical compositions for use in the Field, and an exclusive license, or, in the case of Third Party Patent Rights licensed to Licensor, an exclusive sub license or, in the event that an exclusive sublicense may not be granted to Licensee under the terms of the license granted to Licensor, a sublicense to the full extent permitted under the terms of the license granted to Licensor, including the right to grant sublicenses, under the Patent Rights licensable or sublicensable by Licensor, including Licensors rights in any jointly owned Patent Rights, to further develop Candidate Compounds and Recommended Compounds in connection with the development of pharmaceutical compositions for use in the Field, and make, have made, use, offer to sell, sell and import Products incorporating Licensed Compounds, and Licensed Compounds for use in Products, in the Territory.

For the Manufacturing, the Licensee, its Affiliates and permitted sublicensees shall have the exclusive license to manufacture Compounds and Products.

For the Transfer of Screening Technology, Licensor grants a nonexclusive, perpetual, irrevocable, worldwide license, including the right to grant sublicenses, under all of its intellectual property rights related to the FBPase screening technology to enable Licensee to exercise its rights, including, without
limitation, the development of Candidate Compounds, Recommended Compounds and Research
Compounds.

License Property

The Licensed Compound is CS917, a product candidate for the treatment of type 2 diabetes.

Compound shall mean a Research Compound, Recommended Compound, Candidate Compound or Licensed Compound.

Licensed Compound shall mean a Candidate Compound which Licensee has deemed a Licensed Compound.

Products shall mean pharmaceutical compositions incorporating a Licensed Compound. All formulations of the same drug substance for the same route of administration, such as oral, parenteral or intravenous, shall constitute a single Product.

Field of Use

Field means the treatment of Diabetes by means of lowering blood glucose levels by direct suppression of hepatic gluconeogenesis by inhibiting fructose-1, 6-bisphosphatase.

License Grant

The option shall provide the Japanese Licensee an exclusive option to obtain an exclusive license to a new Back-up Compound for CS-917 and an exclusive first right to negotiate a new agreement with Licensor
for discovery and commercialization of next generation compounds in the Field.

For the grant of option, Licensor grants to the Japanese Licensee an exclusive option to obtain an exclusive license to any one New Back-up Compound discovered by Licensor during the Discovery Period, and,  of the Restated Agreement and otherwise on the terms and conditions set forth in the Restated Agreement.

For grant of negotiation right with Licensor during the Option Term for a new collaborative research, development and commercialization agreement between the parties for the discovery, development and commercialization of Next Generation Compounds in the Field.

License Property

Back-up Compound means any and all Compounds that have properties, results and effects that are substantially similar to CS-917.

CS-917 means that certain Compound known as CS-917 (also known as MB6322), which is a Licensed Compound under the Restated Agreement.

CS-917, a compound for the treatment of type 2 diabetes, is a prodrug of an orally active, potent and selective inhibitor of fructose-1, 6-bisphosphatase (FBPase), a regulatory enzyme in the pathway responsible for the production of glucose in the liver, known as the gluconeogenesis pathway.

Field of Use

Field means the treatment of Diabetes by means of lowering blood glucose levels by direct suppression of hepatic gluconeogenesis by inhibiting fructose-1, 6-bisphosphatase.

License Grant

The French Licensor grants back an exclusive, worldwide, irrevocable and perpetual license, including the right to sublicense through multiple tiers of sublicense, under the Licensors Technology and interest in Joint Patents, to research, develop, make, have made, use, sell, have sold, offer for sale and import Collaboration Compounds outside of the Field.

License Property

Proprietary compounds relating to chronic treatment SERCA activators.  Compounds relates to small molecule SERCA2b modulators for the treatment of type 2 diabetes and other metabolic diseases.

Field of Use

This agreement is for the study of the treatment of type 2 Diabetes, but not on humans.

License Grant

Pursuant to this agreement, the Parties agree to collaborate on an exclusive basis in the Development and Commercialization of Product in the Field.

Licensor grants an exclusive license in the Territory, with the right to sublicense, under the Licensor Rights existing as of the Effective Date, solely to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Field in the Territory as contemplated by this Agreement and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Licensor grants a non-exclusive, worldwide license, including the right to sublicense in conjunction with a sublicense permitted by this agreement, to use the Licensors Marks on Product packaging, labeling, advertising and Promotional Material.

For IT improvements, Licensor grants a worldwide, nonexclusive license in the Territory to practice under the rights of Licensor to any such Licensor Rights and Improvements to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Territory as contemplated by this Agreement and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Each Party grants the other Party an exclusive option to enter into an agreement for the Development of Option Compound(s) Controlled by the granting Party.

License Property

The Neogenesis patents are claiming differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4.

The Compound means exendin-4, an amino acid sequence.

AC2993 (synthetic exendin-4) is a peptide that has been shown to stimulate insulin secretion when blood glucose concentrations are high, but not when blood glucose levels are low.

The Product means a pharmaceutical product that contains or incorporates Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration (including, without limitation, all delivery devices or other peripherals and consumables).

U.S. 5,424,286

Field of Use

The field means prevention and treatment of all human and animal diseases and disorders.

This collaboration agreement is for development and sale of a potential new treatment for type 2 diabetes.